Form 4: Recursion Pharmaceuticals Director Receives Equity Compensation

Recursion Pharmaceuticals, Inc. Director Zavain Dar acquired 2,924 shares of Class A Common Stock on July 1, 2025, as part of the company's Outside Director Compensation Policy.

Summary

• Director Zavain Dar acquired 2,924 shares of Recursion Pharmaceuticals, Inc. Class A Common Stock.
• The transaction occurred on July 1, 2025.
• The shares were acquired at a price of $0, indicating they were issued as compensation rather than purchased.
• Following this transaction, Zavain Dar beneficially owns a total of 135,817 shares of Class A Common Stock.
• The acquisition was made pursuant to the Issuer's Outside Director Compensation Policy.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as compensation, generally signals alignment of interests and confidence in the company's future, contributing to a positive sentiment. It is a routine event, but still viewed favorably.

Positives

• Director Zavain Dar's acquisition of 2,924 shares aligns his interests with those of shareholders, demonstrating continued commitment to the company's performance.
• The issuance of shares as part of the Outside Director Compensation Policy is a standard practice for incentivizing and retaining experienced board members.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director aligns their financial interests with those of shareholders, potentially reinforcing confidence in management's commitment to long-term value creation.

Key Dates

Recommendation

Keywords

Recursion Pharmaceuticals, RXRX, SEC Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Zavain Dar, Equity Compensation